News
CANF
3.010
-1.63%
-0.050
Can-Fite BioPharma director Guy Regev files initial beneficial ownership statement
Reuters · 22h ago
Weekly Report: what happened at CANF last week (0330-0403)?
Weekly Report · 1d ago
Can-Fite BioPharma files to sell 3.29M ordinary shares for holders
TipRanks · 03/31 10:16
Can-Fite and Vetbiolix Complete Phase 2 Enrollment for Canine Osteoarthritis Drug Piclidenoson
TipRanks · 03/30 12:05
Can-Fite BioPharma completes enrollment in Piclidenoson study
TipRanks · 03/30 11:37
Can-Fite Biopharma's Veterinary Partner Vetbiolix Completes Enrollment In Phase 2 Study Of Piclidenoson For Osteoarthritis In Dogs; Topline Data Are Expected In Q3 2026
Benzinga · 03/30 11:25
CAN FITE BIOPHARMA LTD - CAN-FITE SIGNS DEAL WITH VETBIOLIX WORTH UP TO $325 MLN
Reuters · 03/30 11:20
Can-Fite partner Vetbiolix completes enrollment in Phase 2 canine osteoarthritis trial of Piclidenoson
Reuters · 03/30 11:20
Weekly Report: what happened at CANF last week (0323-0327)?
Weekly Report · 03/30 09:42
Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026
Barchart · 03/30 06:20
Can-Fite BioPharma Posts 2025 Loss but Highlights Long-Term Cancer Survival and Clinical Progress
TipRanks · 03/26 13:52
Can-Fite Biopharma GAAP EPS of -$5.97, revenue of $0.41M
Seeking Alpha · 03/26 13:29
CAN-FITE REPORTS 2025 FINANCIAL RESULTS AND ONGOING CLINICAL PROGRESS HIGHLIGHTING POSITIVE DATA IN PHASE 2A PANCREATIC CANCER AND 9 YEARS CANCER-FREE SURVIVAL IN LIVER CANCER PATIENT
Reuters · 03/26 13:27
Weekly Report: what happened at CANF last week (0316-0320)?
Weekly Report · 03/23 09:40
Can-Fite BioPharma Director Abraham Sartani Files Initial Beneficial Ownership Statement
Reuters · 03/18 12:14
Can-Fite BioPharma VP Business Development Sari Fishman files Form 3 initial beneficial ownership statement
Reuters · 03/18 12:12
Can-Fite BioPharma Ltd. files Form 3 as Chief Scientific Officer Pnina Fishman reports 88 ordinary shares
Reuters · 03/18 12:11
Can-Fite BioPharma CEO, CFO and COO Motti Farbstein files Form 3 initial beneficial ownership statement
Reuters · 03/18 12:10
Can-Fite Secures Israeli Patent to Bolster Namodenoson Anti-Obesity Franchise
TipRanks · 03/17 12:33
Can-Fite BioPharma announces Israeli patent allowance for namodenoson
TipRanks · 03/17 11:50
More
Webull provides a variety of real-time CANF stock news. You can receive the latest news about Can-Fite BioPharma Ltd. through multiple platforms. This information may help you make smarter investment decisions.
About CANF
Can Fite Biopharma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.